|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 270 USD | +0.22% |
|
+0.39% | -6.26% |
| Apr. 26 | Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe | MT |
| Apr. 26 | Amgen to Seek European OK of Thyroid Eye Disease Drug Tepezza | DJ |
March 16 (Reuters) - Amgen Inc:
* AMGEN - ANNOUNCED CHANGES THAT WILL RESULT IN A REDUCTION OF OUR WORKFORCE BY APPROXIMATELY 450 JOBS, REPRESENTING LESS THAN 2% OF OUR TOTAL WORKFORCE
* AMGEN - MADE CHANGES IN WORKFORCE REDUCTION TO REALIGN CO'S EXPENSE BASE IN FACE OF INTENSIFYING PRESSURE ON DRUG PRICES AND HIGH LEVELS OF INFLATION TO CONTINUE TO DELIVER VALUE FOR OUR PATIENTS, STAFF AND SHAREHOLDERS Further company coverage:
| 1st Jan change | Capi. | |
|---|---|---|
| -6.26% | 144B | |
| +25.83% | 653B | |
| +27.00% | 556B | |
| -6.76% | 354B | |
| +20.34% | 331B | |
| +3.00% | 296B | |
| +13.09% | 233B | |
| +5.46% | 201B | |
| -9.61% | 193B | |
| -11.77% | 143B |
AMGEN INC. 
